The use of PX-104 improved insulin sensitivity and decreased serum GGT and ALT levels after 4 weeks of treatment without increasing serum cholesterol or alkaline phosphatase; however, there was no change in hepatic steatosis measured by 1H‐MRS and PDFF-MRI. The gene discussed is INS; the disease is Hepatic steatosis.